De Soyza Anthony, Mawson Philip, Hill Adam T, Elborn Stuart, Bradley Judy M, Haworth Charles S, Floto R Andres, Wilson Robert, Loebinger Michael R, Carroll Mary, Crichton Megan, Chalmers James D, Sullivan Anita, Brown Jeremy, Hurst John R, Duckers Jamie, Kelly Martin, Steer John, Gatheral Tim, Walker Paul P, Winstanley Craig, McGuire Alistair, Denning David, McNally Richard
Population and Health Science Institute, Newcastle University, National Institute of Health Research Biomedical Research Centre, Newcastle, UK.
Newcastle University, Newcastle, UK.
ERJ Open Res. 2021 Apr 19;7(2). doi: 10.1183/23120541.00775-2020. eCollection 2021 Apr.
Bronchiectasis has been a largely overlooked disease area in respiratory medicine. This is reflected by a shortage of large-scale studies and lack of approved therapies, in turn leading to a variation of treatment across centres. BronchUK (Bronchiectasis Observational Cohort and Biobank UK) is a multicentre, prospective, observational cohort study working collaboratively with the European Multicentre Bronchiectasis Audit and Research Collaboration project. The inclusion criteria for patients entering the study are a clinical history consistent with bronchiectasis and computed tomography demonstrating bronchiectasis. Main exclusion criteria are 1) patients unable to provide informed consent, 2) bronchiectasis due to known cystic fibrosis or where bronchiectasis is not the main or co-dominant respiratory disease, 3) age <18 years, and 4) prior lung transplantation for bronchiectasis. The study is aligned to standard UK National Health Service (NHS) practice with an aim to recruit a minimum of 1500 patients from across at least nine secondary care centres. Patient data collected at baseline includes demographics, aetiology testing, comorbidities, lung function, radiology, treatments, microbiology and quality of life. Patients are followed up annually for a maximum of 5 years and, where able, blood and/or sputa samples are collected and stored in a central biobank. BronchUK aims to collect robust longitudinal data that can be used for analysis into current NHS practice and patient outcomes, and to become an integral resource to better inform future interventional studies in bronchiectasis.
支气管扩张症在呼吸医学领域一直是一个很大程度上被忽视的疾病领域。这体现在大规模研究的匮乏以及缺乏获批疗法上,进而导致各中心的治疗方法存在差异。英国支气管扩张症研究(BronchUK,英国支气管扩张症观察队列与生物样本库)是一项多中心、前瞻性、观察性队列研究,与欧洲多中心支气管扩张症审计与研究合作项目合作开展。进入该研究的患者纳入标准是临床病史符合支气管扩张症且计算机断层扫描显示有支气管扩张症。主要排除标准为:1)无法提供知情同意书的患者;2)已知由囊性纤维化导致的支气管扩张症或支气管扩张症并非主要或共同主导的呼吸系统疾病;3)年龄<18岁;4)既往因支气管扩张症接受过肺移植。该研究与英国国家医疗服务体系(NHS)的标准做法保持一致,旨在从至少九个二级护理中心招募至少1500名患者。基线时收集的患者数据包括人口统计学信息、病因检测、合并症、肺功能、放射学检查、治疗情况、微生物学以及生活质量。患者每年接受随访,最长随访5年,并且在可行的情况下,采集血液和/或痰液样本并存储在中央生物样本库中。BronchUK旨在收集可靠的纵向数据,可用于分析当前NHS的做法和患者预后,并成为一个不可或缺的资源,以便更好地为未来支气管扩张症的干预性研究提供信息。